Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Xoft, Inc.
The purpose of this multi-center clinical study is to compile post market performance and safety data on the Axxent System for the delivery of radiation therapy as part of breast conserving therapy in women with resected, early stage breast cancer.
Age
50–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Age \>50 years
Tumor with Tis, T1, N0, M0 - (AJC Classification)
Invasive ductal carcinoma or ductal carcinoma in situ
Negative microscopic surgical margins of at least 1mm in all directions
Adequate skin spacing between balloon surface and surface of the skin - (\> 7mm)
You may not be if
Pregnancy or breast-feeding - (During the treatment portion of the study, sexually active women of childbearing age will be asked to use pregnancy prevention)
Scleroderma, systemic sclerosis and active lupus
Infiltrating lobular histology
Clareo Health | Post Market Study Using the Xoft Axxent System
